Mounting evidence has linked postnatal antibiotic use with body mass index (BMI) in children, but the influence of prenatal antibiotic use on offspring obesity risk remains unclear. We aimed to assess the association between fetal exposure to antibiotics and obesity at ages 4 and 7 years among 43,332 children using a multicenter prospective cohort of the US Collaborative Perinatal Project (1959)(1960)(1961)(1962)(1963)(1964)(1965)(1966)(1967)(1968)(1969)(1970)(1971)(1972)(1973)(1974)(1975)(1976). Antibiotic use was ascertained for mothers during pregnancy. Modified Poisson regression models were used to estimate risk ratios for obesity (BMI >95th percentile), and linear mixed models were applied to assess the association with BMI z score. Repeated prenatal exposure to antibiotics was associated with childhood obesity at age 7 years, and risk of obesity tended to increase with an increasing number of antibiotic exposures (for 2-3 exposures, risk ratio (RR) = 1.22, 95% confidence interval (CI): 1.04, 1.44; for ≥4 exposures, RR = 1.34, 95% CI: 1.03, 1.73). The magnitude of association was strongest for repeated exposures in the second trimester (RR = 1.40, 95% CI: 1.16, 1.71). Prenatal antibiotic use was not associated with obesity or BMI z score at age 4 years. These findings support an increased risk of mid-childhood obesity with repeated use of antibiotics during pregnancy.
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Mounting evidence has linked postnatal antibiotic use with body mass index (BMI) in children, but the influence of prenatal antibiotic use on offspring obesity risk remains unclear. We aimed to assess the association between fetal exposure to antibiotics and obesity at ages 4 and 7 years among 43,332 children using a multicenter prospective cohort of the US Collaborative Perinatal Project (1959) (1960) (1961) (1962) (1963) (1964) (1965) (1966) (1967) (1968) (1969) (1970) (1971) (1972) (1973) (1974) (1975) (1976) . Antibiotic use was ascertained for mothers during pregnancy. Modified Poisson regression models were used to estimate risk ratios for obesity (BMI >95th percentile), and linear mixed models were applied to assess the association with BMI z score. Repeated prenatal exposure to antibiotics was associated with childhood obesity at age 7 years, and risk of obesity tended to increase with an increasing number of antibiotic exposures (for 2-3 exposures, risk ratio (RR) = 1.22, 95% confidence interval (CI): 1.04, 1.44; for ≥4 exposures, RR = 1.34, 95% CI: 1.03, 1.73). The magnitude of association was strongest for repeated exposures in the second trimester (RR = 1.40, 95% CI: 1.16, 1.71). Prenatal antibiotic use was not associated with obesity or BMI z score at age 4 years. These findings support an increased risk of mid-childhood obesity with repeated use of antibiotics during pregnancy.
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Childhood obesity is a challenging public health crisis worldwide (1) . Between 1980 and 2013, the global prevalence of childhood overweight and obesity increased by about 50% (2) . Obesity in childhood is associated with adverse cardiometabolic outcomes such as type 2 diabetes, fatty liver disease, dyslipidemia, and hypertension in adulthood (3) . In addition to well-known risk factors including genetic predisposition, excess energy intake, and less physical activity (1) , emerging evidence has identified that disturbances in microbial diversity and composition of the gut could affect host energy metabolism and lead to obesity (4) (5) (6) .
Antibiotics have been used to promote weight gain in livestock for more than half a century (7) . This effect was hypothesized to be mediated by the gut microbiome. Findings from animal models suggest that alteration of the microbiota due to antibiotic exposure in early life, even if it is a short-term use, may be sufficient to induce lasting metabolic consequences (8) (9) (10) . Randomized controlled trials have also shown that antibiotics also promote weight gain in humans (11) (12) (13) (14) .
Epidemiologic studies of early-life exposure to antibiotics and the development of body mass in children mostly focused on postnatal antibiotic use. The majority of the studies demonstrated that antibiotic exposure in infancy was associated with an increased risk of childhood obesity (15) (16) (17) . Two prior studies observed a positive association between prenatal exposure to antibiotics and obesity in children at school ages (18, 19) . However, 2 recent studies examining antibiotic use during pregnancy and body mass index (BMI) in early childhood reported conflicting results (20, 21) . Although such evidence suggests the potential role of prenatal antibiotic use in offspring weight gain, substantial uncertainty still remains regarding the influence of different antibiotic types and timing of the first exposure. Moreover, the sample sizes of several previous studies were relatively small.
Antibiotics are among the most commonly dispensed drug classes in pregnancy (22) . Therefore, a better understanding of the association between prenatal antibiotic exposure and childhood obesity may have important public health implications. The present study aimed to evaluate the impact of prenatal antibiotic use on the development of obesity among children at 4 and 7 years of age, using data from a historical prospective birth cohort, the US Collaborative Perinatal Project (CPP).
METHODS

Study design and participants
The CPP was a prospective cohort study that recruited approximately 46,000 women who gave birth to nearly 59,000 babies at 12 medical centers across the United States during [1959] [1960] [1961] [1962] [1963] [1964] [1965] . During the study period, 18% of the women gave birth to more than 1 child. Women were routinely interviewed during pregnancy, and their children were followed through age 7 or 8 years with systematic assessments of neurological and cognitive development, physical growth, and other health parameters. The CPP has been described in detail previously (23) .
Anthropometric data captured at approximately ages 4 years (46-52 months) and 7 years (82-90 months) were employed to assess study outcomes; there was strong clustering of measurements at these times, with fewer children measured outside these age ranges (24) . The primary outcome of interest for this study was childhood obesity; therefore, measurements at younger ages (e.g., in infancy) were not applicable. The present analysis focused on live singleton births with complete records of prenatal antibiotic use and child weight and height measurements at ages 4 or 7 years. Women could be enrolled again in subsequent pregnancies. The institutional review board of our hospital granted an exemption from ethics review because the CPP data are deidentified for public use.
Antibiotic exposure
At enrollment and each prenatal visit, use of drugs including antibiotics was ascertained by maternal self-report. Women reported the type of drugs used and the number of days the drugs were taken in each month of pregnancy. Antibiotic exposure was defined as a systemic antibacterial agent use at any time during pregnancy. Timing of first exposure to antibiotics was grouped into the first trimester (month 1-3), second trimester (month 4-7), or third trimester (month 8 to delivery) of gestation. The number of antibiotics taken was used as a surrogate for antibiotic courses because actual courses could not be discerned in the CPP data. Different types of antibiotics were identified as follows: penicillins, sulfonamides, tetracyclines, nitrofurans, aminoglycosides, chloramphenicol, macrolides, and others. Of these, penicillins were classified as narrow spectrum, and all other antibacterial agents were classified as broad spectrum.
Outcome measures
Children had their height and weight measured at ages 4 and 7 years by trained personnel. Height was measured to the nearest 0.5 cm using a standardized backboard, and weight was recorded in pounds to the nearest 0.25 pounds or grams to the nearest 100 g using scales calibrated semiannually (25) . BMI was calculated as weight in kilograms divided by height in meters squared. Ageand sex-specific BMI z scores and percentiles were calculated based on the Centers for Disease Control and Prevention (CDC) 2000 growth charts (26) . Overweight or obese status was defined as BMI ≥85th percentile and obesity as BMI ≥95th percentile. The primary outcome was childhood obesity at 2 time points. Overweight or obesity (hereafter referred to as overweight unless otherwise noted) and BMI z scores were modeled as the secondary outcomes.
Statistical analysis
The association between prenatal antibiotic exposure and childhood overweight and obesity was initially evaluated by logbinomial regression. Because convergence problems arose with binomial regression models, modified Poisson regression was finally used to estimate risk ratios and 95% confidence intervals (27) . To account for correlation in the data resulting from sibling clusters, generalized estimating equations were used to provide robust standard errors. Linear mixed models with an unstructured correlation matrix and a random intercept were used to assess the association of antibiotic exposure with BMI z score. Separate models were fitted for each outcome at ages 4 and 7 years, respectively. We examined whether the exposure-outcome association differed across pregnancy by fitting trimester-specific models and investigated the effect estimates of cumulative exposure to antibiotics by categorizing the number of antibiotic exposures as none, 1, 2-3, or ≥4 times. Interactions between timing of first antibiotic use and the number of uses were evaluated by dividing them into 7 groups: No antibiotic (referent), single use in first trimester, repeated use in first trimester, single use in second trimester, repeated use in second trimester, single use in third trimester, and repeated use in third trimester. The impacts of different types of antibiotics were determined through similar analyses within narrow-and broad-spectrum categories as well as within specific antibiotic types.
Models adjusted for potential confounders selected a priori, including maternal age (continuous), race (white, black, and other), socioeconomic index (5 categories), smoking during pregnancy (yes/no), prepregnancy BMI (continuous), and center (12 strata). Other potential confounders were considered using a change in risk ratio of ≥10%. None of the tested variables (e.g., child sex, mode of delivery) except parity (0, 1, >1 prior births) was added for adjustment. Because of missing values for prepregnancy BMI (8% of observations) and several other covariates, a multiple imputation approach (by chained equations with 5 replicates) was used for covariates with missing data (28) . Predictors used in this imputation were variables listed in Table 1 and mode of delivery, study center, and childhood BMI. We evaluated effect modification by child sex, race, prepregnancy BMI status (<25, ≥25), and mode of delivery (vaginal, cesarean) by including a cross-product term for these variables.
The robustness of our findings was tested by restricting the analysis to mother-child dyads with complete covariate data. As a sensitivity analysis, regression models were refitted with the outcomes of childhood overweight and obesity that were determined by the International Obesity Task Force age-and sex-specific cutoffs of BMI (29) . To assess the potential bias of loss to follow-up, we conducted another sensitivity analysis using inverse probability weights for successful follow-up (30) . The probability of successful follow-up was calculated in logistic models (separately for 4-year and 7-year visits) that included terms for the abovementioned confounders plus maternal education, birth weight, gestational age, mode of delivery, and diabetes before and during pregnancy. All statistical analyses were performed using SAS, version 9.4 (SAS Institute, Inc., Cary, North Carolina).
RESULTS
Among 53,647 live singleton children in the CPP, 43,665 completed follow-up visits at age 4 or 7 years. Exclusion of children with missing data on prenatal antibiotic exposure and valid BMI measurements resulted in a final study sample of 43,332 children (Web Figure 1 , available at https://academic.oup.com/aje). Of these, 33,228 were eligible for 4-year outcome analysis and 39,615 for 7-year outcome analysis. In this study, 10,908 (25.2%) women used antibiotics during pregnancy. Generally, women with antibiotic exposure were more likely to be younger, black, overweight or obese before pregnancy, at a lower socioeconomic level, or smokers compared with those without exposure ( Table 1) . Of the exposed mothers, more than 40% had repeated use of antibiotics over the entire pregnancy. Penicillins were the most used (56.7%), followed by sulfonamides (39.8%), tetracyclines (13.7%), nitrofurans (4.8%), and other antibiotics were used less frequently (Web Table 1 ). Participants included in the analysis were more likely to be black than were those excluded, and distributions for other baseline characteristics were similar (Web Table 2 ).
At age 4 years, the prevalence of childhood overweight and obesity was 24.7% and of obesity was 8.9%. In the crude analysis, a tendency of inverse relationship between prenatal antibiotic exposure and overweight/obesity was identified (Web Table 3 ). However, after adjusting for potential confounders, prenatal antibiotic use was not associated with 4-year overweight or obesity in children, either cumulatively or according to trimester (Table 2) .
At age 7 years, prevalence of childhood overweight and obesity was 13.1% and of obesity was 4.6%. After adjustment for covariates, there was no general association between prenatal exposure to antibiotics and age-7-years overweight or obesity (Table 2) . Nevertheless, the analysis according to time at first antibiotic use demonstrated a significant association of offspring overweight (risk ratio (RR) = 1.11, 95% confidence interval (CI): 1.02, 1.20) and obesity (RR = 1.19, 95% CI: 1.03, 1.38) with exposure in the second trimester. Children of mothers with repeated antibiotic use during pregnancy had significantly higher risk of obesity compared with those of mothers without antibiotic use (2-3 times, RR = 1.22, 95% CI: 1.04, 1.44; ≥4 times, RR = 1.34, 95% CI: 1.03, 1.73). As for the type of antibiotics, the obesity risk at age 7 years increased with repeated use of narrowspectrum (≥2 times, RR = 1.31, 95% CI: 1.09, 1.56) as well as broad-spectrum drugs (≥2 times, RR = 1.23, 95% CI: 1.04, 1.46) ( Table 3 ). Analysis of the interaction between the timing of first exposure and the number of exposures revealed that repeated antibiotic use (≥2 times) in the second trimester was the major contributor to the risk of age-7-years overweight (RR = 1.15, 95% CI: 1.02, 1.29) and obesity (RR = 1.40, 95% CI: 1.16, 1.71) (Figure 1) . Prenatal antibiotic exposure was not associated with the child's BMI z score at the 2 time points (Table 4) .
Stratified analysis demonstrated the effect modification by mode of delivery on the association between antibiotic use and childhood obesity (Web Table 4 ). Compared with children born vaginally (RR = 1.18, 95% CI: 1.02, 1.38), those born by cesarean delivery presented a stronger association with 7-year obesity (RR = 1.77, 95% CI: 1.21, 2.60). There was no evidence of the child's sex, maternal prepregnancy BMI, or race as the effect modifiers. Assessments of impacts of specific antibiotic types indicated that maternal exposure to tetracyclines (RR = 1.26, 95% CI: 1.01, 1.57) and aminoglycosides (RR = 1.58, 95% CI: 1.02, 2.45) was related to obesity at age 7 years (Web Figure 2) .
The results did not change materially after restricting the analysis to observations with complete covariate data (Web Table 5 ). When the models were refitted with outcomes of overweight and obesity defined by the cutpoints recommended by the International Obesity Task Force, results were consistent, confirming the association of repeated antibiotic exposures during pregnancy with mid-childhood obesity (Web Table 6 ). The results were similar when the data were weighted by the inverse probability of follow-up (or being examined) at each time point (Web Table 7 ).
DISCUSSION
Within the context of the longitudinal CPP data, we examined prenatal exposure to antibiotics in relation to childhood overweight and obesity at ages 4 and 7 years. Our study did not observe a significant general association between prenatal antibiotic use and childhood obesity. Repeated antibiotic use, however, was associated with age-7-years obesity, and the risk tended to increase with an increasing number of antibiotic uses. Antibiotic exposure during pregnancy was not associated with age-4-years obesity risk. Similarly, no associations with childhood BMI z score at the 2 time points were observed.
There has been little information on prenatal antibiotic use and childhood obesity or BMI. Two prior studies indicated an association between prenatal exposure to antibiotics and an increased risk of offspring obesity at ages 7-16 years (18, 19) . Consistent with our study, an increasing risk of obesity with higher numbers of maternal antibiotic prescriptions has been demonstrated (19) . However, other investigators have recently published studies with conflicting results in relation to BMI in early childhood. One group reported that prenatal antibiotic use was associated with larger BMI at age 2 years (20) , whereas the other failed to observe such a relationship with BMI at age 3 years (21). In comparisons with prior studies, the strength of the association observed in our study was relatively weak. However, the robustness and reliability are supported by serial sensitivity analyses. These findings may suggest a potential role for prenatal antibiotic use, particularly repeated use, in childhood adiposity at school age.
The underlying mechanisms by which prenatal antibiotic exposure has growth-promotion effects may be related to antibioticinduced perturbations of maternal microbiota. Altered maternal gut and vaginal microbiota would directly affect the postnatal metabolism for newborns by changing the composition of the "pioneer" microbiota upon delivery (31, 32) . Mounting evidence has also emerged to indicate that the fetus may be exposed to maternal gut microbes prenatally; studies have found a diverse range of microbes in umbilical cord blood, placenta, amniotic fluid, meconium, and fetal membranes in healthy normal pregnancies (33) . Importantly, the microbes in meconium had a distinct microbiome that included similarities with the amniotic fluid and placenta (34) . These results suggest that maternal-fetal exchange of commensal microbiota might exist before birth (33) (34) (35) . Intrauterine maternal microbiota can drive intestinal transcriptional programming in offspring that are consistent with adapting early postnatal immune and metabolic functions (36) . In this light, antibiotic use, particular repeated use, in pregnancy is likely to alter maternal microbial communities and disrupt normal colonization of the fetus intestinal microbiome, which might have longlasting metabolic consequences later in life (8) (9) (10) .
Antibiotic exposure during pregnancy has been associated with low birth weight and methylation of imprinted genes involved in early growth and development (37) . Similarly, a nonsignificant inverse association was observed between prenatal antibiotic exposure and birth weight in the present study. Further adjustment for birth weight did not alter the associations between antibiotics and childhood obesity. It remains to be elucidated whether somatic epigenetic changes in response to prenatal antibiotic exposure also contribute to adiposity in childhood.
Repeated exposure to antibiotics in the second trimester showed the most pronounced association with childhood obesity risk. The fetal intestine undergoes rapid development during mid-to-late gestation (38) and, therefore, this period could be a window of particular susceptibility to antibiotics. Additionally, evidence suggests that repeated antibiotic use could preclude the recovery of gut Abbreviations: BMI, body mass index; CI, confidence interval; RR, risk ratio. a Includes children classified as overweight or obese. Overweight or obese status was defined as BMI ≥85th percentile and obesity as BMI ≥95th percentile.
b Adjusted for maternal age, race, socioeconomic index, smoking during pregnancy, prepregnancy BMI, parity, and center. Multiple imputation was used for covariates with missing values.
c Eighty-two participants with unknown exposure month were not included. d One hundred thirty participants with unknown exposure month were not included.
microbiota from antibiotic-induced perturbations, resulting in a persistent, antibiotic-altered microbiota composition (39) . Our study identified mode of delivery as a potential effect modifier. Because antibiotics are routinely administered prophylactically in cesarean delivery, it is possible that intrapartum antibiotic exposure constitutes an additional perturbation to these children, which is manifested as a stronger association in this group. The present study has, to our knowledge, by far the largest sample size of the studies published on this topic. Height and weight of children from the CPP were measured by trained personnel who were unaware of the child's exposure status; thus, differential misclassification of the outcomes was unlikely. Furthermore, CPP collected detailed demographic and medical information as well as patterns of antibiotic use at each prenatal visit, which made it possible for us to control for multiple confounders. The prospective design and long follow-up period enabled us to assess the associations in both early and mid-childhood.
On the other hand, the CPP was conducted a few decades ago, creating a major limitation to the potential applicability of the results to today's conditions. Some antibiotics have passed out of use, and the patterns of antibiotic use during pregnancy might have also changed. For example, sulfonamides and tetracyclines accounted for more than 80% of the broad-spectrum antibiotics issued during pregnancy in the CPP, and macrolides were the least used. Today, macrolides are the most commonly prescribed Figure 1 . Adjusted risk ratios for childhood overweight and obesity at 7 years of age, associated with maternal trimester-specific antibiotic use and number of exposures, Collaborative Perinatal Project, United States, 1959-1976. Overweight or obese status (denoted with circles) was defined as BMI ≥85th percentile and obesity (denoted with squares) as BMI ≥95th percentile. Models adjusted for maternal age, race, socioeconomic index, smoking during pregnancy, prepregnancy body mass index, parity, and center. Children born to mothers who did not take any antibiotics during pregnancy were the referent. Points indicate risk ratios, with 95% confidence intervals shown by lines. Filled circle or square: single antibiotic use during pregnancy; white circle or square: repeated use.
broad-spectrum agents (40) . Currently, although sulfonamides and tetracyclines are not officially recommended for pregnant women unless indicated due to potential fetal risk (41) , both have still been commonly dispensed (more than 2% of the time) due to lack of safety evidence to inform treatment decisions or inappropriate use in the United States during the past two decades (40, 42) . Moreover, penicillins remain the most used antibiotics in pregnancy (22, 40, 42) . As such, it is still relevant to assess the metabolic consequences of these antibiotics to better understand their longterm safety.
Admittedly, not only the prevalence but also the nature of childhood obesity has changed over the past several decades (43) . For example, excess energy intake among mothers and children, which was uncommon then, is one of the main contributors now. Lack of physical activity is another major driving factor for obesity. Unfortunately, we had no data from the CPP on maternal or childhood diets or physical activities. However, if these unmeasured factors were not associated with prenatal antibiotic use, they should not have significant confounding effects on the association between prenatal exposure to antibiotics and childhood obesity.
Confounding by the indications for which antibiotics were used was another concern in this study. The CPP did not record information on the specific infection that led to the use of antibiotics. It is, therefore, possible that the observed association was confounded by the underlying infection. But this may not explain our results, as the most common infection diagnoses for antibiotic administration during pregnancy include acute upper respiratory infections and urinary tract infections, which suggests that antibiotics prescribed for common and acute infections are unlikely to affect offspring weight (21) . Second, information on postnatal exposure to antibiotics was not available in the CPP. Thus, if maternal prenatal antibiotic use is correlated with infant use of antibiotics, the association in our study was at least partly due to the influence of postnatal antibiotic exposure. To the best of our knowledge, however, there is no evidence to support a strong correlation between maternal and infant antibiotic use. Last, information on antibiotic use during pregnancy relied on selfreport. Even so, recall bias is unlikely to occur because the data were captured through multiple prenatal visits in different stages of pregnancy. If some women did underreport their antibiotic use and were misclassified as unexposed, the association between prenatal antibiotic use and child obesity would tend to be attenuated.
In conclusion, our results suggest that repeated antibiotic use during pregnancy was associated with risk of childhood obesity. The obesity risk was greatest for children of mothers who used antibiotics repeatedly in the second trimester. Given the high antibiotic prescription rates for pregnant women and the obesity epidemic in children, future studies are warranted to confirm the relationship between prenatal exposure to antibiotics and childhood obesity in contemporary populations, and to determine how intrauterine exposure could induce metabolic disorders of offspring.
